Literature DB >> 20540482

Treatment of allergic rhinitis.

Denise K Sur1, Stephanie Scandale.   

Abstract

Allergic rhinitis is a common chronic respiratory illness that affects quality of life, productivity, and other comorbid conditions, including asthma. Treatment should be based on the patient's age and severity of symptoms. Patients should be advised to avoid known allergens and be educated about their condition. Intranasal corticosteroids are the most effective treatment and should be first-line therapy for mild to moderate disease. Moderate to severe disease not responsive to intranasal corticosteroids should be treated with second-line therapies, including antihistamines, decongestants, cromolyn, leukotriene receptor antagonists, and nonpharmacologic therapies (e.g., nasal irrigation). With the exception of cetirizine, second-generation antihistamines are less likely to cause sedation and impair performance. Immunotherapy should be considered in patients with a less than adequate response to usual treatments. Evidence does not support the use of mite-proof impermeable covers, air filtration systems, or delayed exposure to solid foods in infancy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20540482

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  15 in total

1.  Older adults' use of care strategies in response to general and upper respiratory symptoms.

Authors:  Joanne C Sandberg; Joseph G Grzywacz; Cynthia K Suerken; Kathryn P Altizer; Sara A Quandt; Ha T Nguyen; Ronny A Bell; Wei Lang; Thomas A Arcury
Journal:  J Appl Gerontol       Date:  2013-03-21

2.  Bioactive components of different nasal spray solutions may defeat SARS-Cov2: repurposing and in silico studies.

Authors:  Mohammad Faheem Khan; Waseem Ahmad Ansari; Tanveer Ahamad; Mohsin Ali Khan; Zaw Ali Khan; Aqib Sarfraz; Mohd Aamish Khan
Journal:  J Mol Model       Date:  2022-07-06       Impact factor: 2.172

3.  Efficacy and Safety of Bojungikgi-Tang for Persistent Allergic Rhinitis: A Study Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Authors:  Su Won Lee; Jin Kwan Choi; Yee Ran Lyu; Won Kyung Yang; Seung Hyung Kim; Je Hyun Kim; Si Yeon Kim; Weechang Kang; In Chul Jung; Beom Joon Lee; Jun Yong Choi; Taesoo Kim; Yang Chun Park
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-20       Impact factor: 2.650

Review 4.  [Complications and side effects of conservative treatment of rhinological diseases].

Authors:  I Küster; C Rudack; A Beule
Journal:  HNO       Date:  2018-06       Impact factor: 1.284

5.  Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis.

Authors:  Sayed Mojtaba Abtahi; Sayed Mostafa Hashemi; Sayed Hamidreza Abtahi; Bagher Bastani
Journal:  J Res Med Sci       Date:  2013-05       Impact factor: 1.852

6.  Treatment of allergic rhinitis with ectoine containing nasal spray and eye drops in comparison with azelastine containing nasal spray and eye drops or with cromoglycic Acid containing nasal spray.

Authors:  Nina Werkhäuser; Andreas Bilstein; Uwe Sonnemann
Journal:  J Allergy (Cairo)       Date:  2014-06-01

7.  Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.

Authors:  Mohini Sachin Mahatme; Ganesh Natthuji Dakhale; Kanchan Tadke; Sachin Keshaorao Hiware; S D Dudhgaonkar; Sumit Wankhede
Journal:  Indian J Pharmacol       Date:  2016 Nov-Dec       Impact factor: 1.200

8.  Surveillance of First-Generation H1-Antihistamine Use for Older Patients with Dementia in Japan: A Retrospective Cohort Study.

Authors:  Toshiki Maeda; Akira Babazono; Takumi Nishi
Journal:  Curr Gerontol Geriatr Res       Date:  2018-07-02

9.  Effect of KOB03, a polyherbal medicine, on ovalbumin-induced allergic rhinitis in guinea pigs.

Authors:  Hyo Won Jung; Jin Ki Jung; Young Ho Kim; Jong-Seong Kang; Yong-Ki Park
Journal:  Chin Med       Date:  2012-12-20       Impact factor: 5.455

Review 10.  Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose.

Authors:  Pascal Demoly; Gianni Passalacqua; Moises A Calderon; Tarik Yalaoui
Journal:  Clin Transl Allergy       Date:  2015-12-23       Impact factor: 5.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.